Important Information
IF YOU’RE INTERESTED IN THIS STUDY:
- Please have a look at the information for this trial by clicking STUDY INFORMATION at the bottom of this page.
- The VISIT SCHEDULES link provides information on the dates the study is taking place. Please note that group dates are set, so it’s important that you check your availability and let us know which groups you prefer, and whether you’re flexible for others that you can see.
- If you have any questions, please don’t hesitate to reach out to us!
Study Information
TLC-3595 is being developed for the treatment of diabetes. Insulin resistance is when cells do not recognise or respond to insulin, resulting in a build-up of unused sugar within the blood (high blood glucose) which can damage cells and tissues.
TLC-3595 works by inhibiting an enzyme, which increases the breakdown of fatty acids in cells in the liver, muscles, and other organs. Decreases in excess fatty acids in these cells is expected to lead to improved insulin sensitivity. It is hoped that TLC-3595 may be an effective insulin sensitiser to potentially treat insulin resistance, a significant risk factor for the development of diabetes.
The purpose of this study is to:
• Evaluate how safe and well tolerated TLC-3595 is, in participants with insulin resistance.
• Measure levels of TLC-3595 in the blood over time, following multiple oral doses, in participants with insulin resistance.
• Measure the body’s response to multiple doses of TLC-3595, in participants with insulin resistance.
Study Candidtes
- Males or Females
- Aged 18 – 70 years
- BMI 28 kg/m2 or more
- Meet the diagnostic criteria for insulin resistance
What is Involved?
Study Visits: 7 clinic visits
Reimbursement: $300 per visit for your time and inconvenience plus travel
3x Bone scans and an optional MRI scan